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Acute  gastrointestinal  bleeding  is  among  the most  urgent  situations  in daily  gastroenterological  practise.
Endoscopy  plays  a key  role  in  the  diagnosis  and  treatment  of  such  cases.  Endoscopic  haemostasis  is
probably  the most  important  technical  challenge  that  must  be  mastered  by gastroenterologists.  It  is
essential  for both  the  management  of acute  gastrointestinal  haemorrhage  and  the prevention  of  bleeding
during  high-risk  endoscopic  procedures.  During  the last  decade,  endoscopic  haemostasis  techniques
and  tools  have  grown  in  parallel  with  the  number  of  devices  available  for endotherapy.  Haemostatic
powders,  over-the-scope  clips,  haemostatic  forceps,  and  other  emerging  technologies  have  changed  daily
practise  and  complement  the  standard  available  armamentarium  (injectable,  thermal,  and  mechanicalaemostatic  powders
emospray
ver-the-scope clips
therapy).  Although  there  is a lack  of  strong  evidence-based  information  on  these procedures  because
of  the  difﬁculty  in  designing  statistically  powerful  trials  on  this  topic,  physicians  must  be aware  of  all
available  devices  to be  able  to choose  the best  haemostatic  tool  for the  most effective  procedure.  We  herein
present  an  overview  of procedures  and  clinical  scenarios  to optimise  the  management  of  gastrointestinal
bleeding  in daily  practise.
 terol
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. Introduction
Endoscopic haemostasis is one of the greatest technical chal-
enges that must be mastered by endoscopists. This procedure is
ssential for both the management of acute gastrointestinal hae-
orrhage and the performance of more advanced interventional
rocedures, such as endoscopic submucosal dissection (ESD), in
hich haemostasis is considered to be part of the endoscopic ther-
py and not an adverse event.
Historically, three groups of devices have been available [1]:
njection therapy, which is the oldest technique and usually
nvolves injection of epinephrine; mechanical therapy with clips,
oops, or ligation; and thermal therapy with argon plasma coagu-
ation (APC) and bipolar or monopolar probes.
Several new endoscopic haemostasis technologies have been
eveloped over the years in part due to close collaboration between
Open access under CC BY-NC-nternational experts and industry suppliers. Self-expanding metal
tents, haemostatic forceps, haemostatic powders, and over-the-
cope clips are currently being used in endoscopic haemostasis.
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ttp://dx.doi.org/10.1016/j.dld.2014.05.008
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Opogica  Italiana  S.r.l.  Published  by  Elsevier Ltd.
Physicians must be aware of all available devices to allow for an
informed decision when selecting a particular device and thus
ensure the most effective outcome. We  herein review the literature
on this practical topic.
A  literature search was  performed using PubMed and Medline.
The following terms were used alone or in combination: endoscopic
haemostasis, gastrointestinal bleeding, haemostatic devices, bleed-
ing ulcers, diverticulosis, variceal bleeding, Hemospray, Ankaferd
Blood Stopper, EndoClot, over-the-scope clip system (OTSC),
haemostatic forceps, Mallory–Weiss syndrome, Dieulafoy’s lesion,
gastric antral vascular ectasia, gastro-oesophageal varices, diver-
ticular bleeding, angiectasia, radiation proctitis, polypectomy, ESD,
endoscopic mucosal resection, sphincterotomy, endoscopic ultra-
sonography, and self-expanding metal stent. We  reviewed this
subject with respect to two areas: emergency haemorrhage and
bleeding during interventional endoscopic procedures.
2.  Upper gastrointestinal haemorrhage (UGIH)
2.1. Non-portal hypertension bleeding
ense.2.1.1. Gastroduodenal ulcers
Gastroduodenal ulcers are by far the most common aetiology of
UGIH, accounting for 50% of admissions among patients with UGIH.
en access under CC BY-NC-ND license.
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nciting factors include nonsteroidal anti-inﬂammatory drugs, Heli-
obacter pylori infection, antiplatelet agents, oral anticoagulants,
nd stress.
Since the 1990s, several studies, including two high-quality
eta-analyses [2,3], have shown that endoscopic therapy in addi-
ion to infusion of proton-pump inhibitors effectively controls
eptic ulcer bleeds. All conventionally available tools can be used
or this indication [4].
Dilute  epinephrine (1:10,000) is available worldwide and
chieves haemostasis through a combination of compression, vaso-
onstriction, and platelet activation. This is probably the easiest
reatment method because it does not require direct viewing dur-
ng the injection and may  be used in tangential lesions when the tip
f the endoscope is angulated or retroﬂexed. If epinephrine is used
lone, there is a signiﬁcant risk of rebleeding: this can be reduced by
njecting large volumes [5,6], which are associated with no clearly
escribed cardiologic adverse events. In two randomised controlled
rials [5,6], immediate haemostasis did not differ between groups,
ut the rebleeding rate decreased linearly with the injected vol-
me: 40 mL  was better than 30 mL,  and 20 mL was  better than
0 mL.
Other  injected substances, such as sclerosing agents (e.g., poli-
ocanol), have similar efﬁcacy but more side effects, such as
ransmural necrosis. One case of delayed gastric perforation has
lso been described [7].
Haemostatic clips are an established tool used to control ulcer
leeds. Various models from different industry suppliers are avail-
ble. Clips differ according to their reopening capacity, rotative
bility, jaw width, and cost. Clipping is easiest when the endoscope
an be maintained in a straight position with the ability to push
t axially into the tissue. Anchoring the clip can be difﬁcult in tan-
ential lesions, such as those requiring haemostasis in retroﬂexion,
ecause the release mechanism can be jammed. One solution is to
ush the clip into a straight position before retroﬂexion. Moreover,
ith the Resolution Clip (Boston Scientiﬁc), removing the plastic
heath allows for ease of handling when lesions require torquing
r retroﬂexion of the scope.
In 2007, a meta-analysis published by Marmo  et al. [8] high-
ighted the role of endoscopic therapy using clips. In this powerful
eta-analysis of 22 studies, which included 2472 patients, dual
ndoscopic therapy was  clearly superior to monoendoscopic ther-
py; however, subcategory analysis failed to demonstrate that
ny speciﬁc combination of treatments was superior to mechan-
cal therapy alone, unlike the use of epinephrine injections alone.
hat same year, a meta-analysis of 15 randomised controlled trials
ncluding 1156 patients and published by Sung et al. [9] showed
he superiority of clipping versus an epinephrine injection alone,
ut not versus thermocoagulation. When technically feasible, clips
ay  be preferable to contact thermal probes because of the lower
isk of perforation.
Thermal therapies usually involve the use of bipolar probes,
hich allow for superﬁcial coagulation. They are very useful for tan-
ential lesions, but there is a risk of perforation. The Injection Gold
robe (Boston Scientiﬁc) is a multifunctional device that allows for
he performance of thermal therapy and injection with a single
atheter.
Endoscopic management is traditionally based on the Forrest
lassiﬁcation of the lesion. Powerful meta-analyses involving more
han 5000 patients were published between 2003 and 2009 (Table
1) and they identiﬁed the best combinations of endoscopic ther-
pies for this indication [8–14]. In patients with ulcers exhibiting
ngoing bleeding or high-risk features (Forrest Ia, Ib, or IIa), the use
f endoscopic therapy with two different methods of haemosta-
is (Fig. 1), including an injection of epinephrine, is recommended
15,16]. Disease 46 (2014) 766–776 767
The choice between mechanical or thermal therapy, in associa-
tion with an injection of epinephrine, will depend of the localisation
and characteristics of the lesion, skill of the endoscopist, available
tools, and nurse training [17]. For a gastroduodenal ulcer with an
adherent clot, the decision to undertake haemostasis needs to be
re-evaluated in each particular situation. However, the literature
remains controversial [18], and the choice is left to the endoscopist.
However, if an endoscopic procedure is attempted, removal of the
clot must be preceded by an injection of epinephrine followed by
thermal therapy or clip placement.
Topical haemostatic agents are new tools used in endoscopic
haemostasis. Three different powders are available: Haemospray
(Cook Medical, Winston-Salem, NC, USA), Ankaferd Blood Stopper,
and more recently, EndoClot (EndoClot Plus Inc., Santa Clara, CA,
USA) [7].
Hemospray is an inorganic powder that was  ﬁrst utilised in
addition to standard gauze to control external bleeding in mili-
tary personnel. Its composition is proprietary, but the powder has
three mechanisms of action [19]. Physically, the powder forms a
mechanical barrier over the bleeding site. It is absorbent and acts
as a serum separator, thus increasing the concentration of clotting
factors. It is also electrostatic due to its negative charge. Finally,
the powder activates the intrinsic clotting cascade. Hemospray is
approved in some regions of the world, including Canada, Hong
Kong, France, and several European countries for nonvariceal upper
gastrointestinal bleeding. The powder is delivered through a 10- or
7-French catheter via a CO2-pressurised canister (Fig. 1). Two  ani-
mal  studies have conﬁrmed its efﬁcacy without any adverse events,
particularly without obstruction or embolic events. A high immedi-
ate haemostasis rate (>90%) has been reported in 11 human studies
[20–30], and a low rebleeding rate has also been reported. Prelimi-
nary results on the use of Hemospray alone or in combination with
other modalities showed successful haemostasis in 89 of 97 (92%)
patients [24]. Table S2 (supplementary data) shows all available
publications on Hemospray used for UGIH [20–30,71,129–137].
This new technology is very promising, but its actual role in the
toolbox of endoscopic haemostasis remains to be deﬁned. Its advan-
tages are its ease of use, acting as an “extinguisher” even in difﬁcult
locations, and its potential efﬁcacy for different bleeding lesions. Its
disadvantages are its cost and the inability to use another modality
should haemostasis fail, as the powder would interfere with other
treatments. Video 1 (supplementary data) shows an example of
Hemospray used on a bleeding ulcer.
One industry-sponsored, nonrandomised, single-group, open-
label study on Hemospray is ongoing in USA (NCT01306864). It
is focused on peptic ulcer bleeds and is evaluating the efﬁcacy of
Hemospray for immediate haemostasis and prevention of rebleed-
ing in 80 patients with bleeding ulcers. However, Hemospray only
works for actively bleeding or oozing lesions. It does not work when
there is no blood, nonbleeding visible vessels, or other nonactively
bleeding lesions.
Ankaferd Blood Stopper (ABS) (Ankaferd Health Products, Ltd.,
Turkey) is a traditional Turkish herbal mixture that has been used
for hundreds of years to treat various cases of complex bleed-
ing. To date, more than 35 papers, all by Turkish teams, have
been published on the haemostatic efﬁciency of ABS for UGIH
of various origins: ulcers [31–34], tumours [35–37], and variceal
bleeding [38–42]. The exact composition of ABS is well known [43]:
100 mL  of the product contains a standardised mixture of plants,
namely 5 mg Thymus vulgaris dried leaf extract, 9 mg  Glycyrrhiza
glabra dried leaf extract, 8 mg  Vitis vinifera dried leaf extract, 7 mg
Alpinia ofﬁcinarum dried leaf extract, and 6 mg  Urtica dioica dried
root extract. However, despite various studies that applied in vitro
[44] and in vivo models [45,46], its exact mechanism of action is
incompletely understood. Technically, ABS is delivered through the
768 J. Jacques et al. / Digestive and Liver Disease 46 (2014) 766–776
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dig. 1. Haemostatic therapy for a bleeding ulcer of the duodenal bulb. (a) Bleeding d
lot. (b and c) Injection therapy with diluted epinephrine. (d–f) Mechanical thera
emospray due to persistent oozing bleeding; before (g), during (h), and at the end
orking channel of the scope using a spray catheter. To the best of
ur knowledge, this product is available only in Turkey.
The  EndoClot Polysaccharide Hemostatic System (EndoClot Plus
nc., Santa Clara, CA, USA) is the latest available haemostatic pow-
er. According to the supplier, it is intended for use as an adjunct
aemostat to control bleeding from capillary, venous, or arteriolar
essels in the gastrointestinal tract. Its composition is very sim-
le: it consists of starch, which explains its availability in European
ountries, Australia, Malaysia, and Turkey despite the lack of rig-
rous scientiﬁc evidence of its efﬁcacy. Only one recent study on
ndoClot has been published; this study described the effective-
ess of the powder for controlling and preventing bleeding related
o endoscopic mucosal resection (EMR) [47] in 181 lesions of 81
atients. The applicator comprises a powder/gas mixing chamber,
 delivery catheter (7-French width, 1800 or 2300 mm length), and
 connecting tube between a gas ﬁlter and external gas source. The
ame manufacturer also sells the EndoClot air compressor as the
ecommended gas source for the powder-delivery system. Video
 shows an application of EndoClot after the piecemeal resection
f a laterally spreading tumour in the caecum of an elderly patient
reated with aspirin (Fig. 2).
In our experience, the Hemospray delivery system acts as an
extinguisher” and seems to be easier to manipulate than the
elivery system of the EndoClot PHS, particularly in emergencies.
ndeed, when operating the EndoClot PHS system, the nurse must
arefully and regularly tap the powder chamber to deliver the pow-
er in a continuous manner.nal ulcer (Forrest Ib) of the duodenal bulb with oozing bleeding under the adherent
th placement of a haemoclip. (g–i) Salvage therapy with the haemostatic powder
 pulverisation.
These emerging technologies for endoscopic haemostasis are
very promising, but more scientiﬁc research and randomised con-
trolled trials are needed to assess their efﬁcacy and safety.
Over-the-scope clip system (OTSC). The OTSC (Ovesco Endoscopy
AG, Tübingen, Germany) is a recent endoscopic device that was pri-
marily developed for endoscopic closure of perforations or ﬁstulas
[48,49]. Clinical data on endoscopic haemostasis with the OTSC are
promising; more than 140 patients have reportedly been treated
with a clinical success rate of 90%. Several different lesions have
been managed with the OTCS, including peptic bleeding ulcers,
Mallory–Weiss syndrome, and anastomotic bleeding. In addition,
an ex vivo study that used an established bleeding model [50] con-
ﬁrmed the efﬁcacy of the OTSC on bleeding lesions with a signiﬁcant
increase in systemic pressure.
According  to the literature, a common location for this device
is the posterior wall of the bulb [51,52]. In this location, standard
clips are difﬁcult to use because of their tangential location, and
exposure to thermal therapy increases the risk of perforation. OTSC
allows suction of a large amount of targeted tissue by releasing the
clip using a hand wheel, similar to band ligation.
The largest study published on the haemostatic role of the OTSC
is a recent retrospective study that reported excellent results in 30
patients (23 patients with UGIH and 7 with lower gastrointesti-
nal bleeds) that had failed to respond to conventional therapies
(adrenaline injection + clips); haemostasis was  achieved in 97% of
these patients using OTSC [51]. Rebleeding occurred in only two
J. Jacques et al. / Digestive and Liver Disease 46 (2014) 766–776 769
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lig. 2. Prevention of delayed bleeding by EndoClot pulverisation post-colonic endos
and  Imaging). (b) Piecemeal resection. (c) Post-EMR scar with the EndoClot pulveri
f  the post-EMR scar covered with powder.
atients, both of whom were successfully treated by conventional
ndoscopic therapy.
aemostatic forceps. These are usually used for prophylactic or
urative haemostasis during large EMRs or ESD of superﬁcial
umours (Fig. 3). A recent nonrandomised prospective trial reported
n the efﬁcacy of using haemostatic forceps for nonvariceal UGIH
53]. A single modality (Coagrasper; Olympus Corp., Tokyo, Japan)
chieved endoscopic haemostasis in 100% of cases, which was
etter than with clipping alone (78.2%), and exhibited success
imilar to that obtained by the combination of clipping and an
drenaline injection. Moreover, although not statistically signiﬁ-
ant, the rebleeding rate was lower (3.7% vs. 22.2%). More than 80%
f lesions were gastric or duodenal ulcers.
.1.2. Mallory–Weiss syndrome
In  Mallory–Weiss syndrome, all haemostatic tools (injectable,
hermal, and mechanical) are equally effective [54]. Several studies
ave compared the efﬁciency of different tools for this indica-
ion. A recent French retrospective study involving 218 patients
55] showed the superiority of band ligation versus clips plus
pinephrine. These results disagree with those of two  small ran-
omised controlled trials [56,57] that compared band ligation
ersus clips or epinephrine and found no difference in the rebleed-
ng rate or immediate haemostasis rate.
.1.3. Dieulafoy’s lesions
In  Dieulafoy’s lesions, mechanical therapies such as clipping [58]
nd ligation [59] are associated with a lower risk of rebleeding than
s an epinephrine injection [60]. Several Dieulafoy’s lesions have
een treated with Hemospray with promising results.
Treatment of Dieulafoy’s lesions and Mallory–Weiss syndrome
mphasise the usefulness of band ligation [59,61] for nonportal
ypertension bleeding lesions, particularly in the oesophagus and
tomach (Fig. 4), because of its ease of use and efﬁcacy in these
ocations. mucosal resection (EMR). (a) Laterally spreading tumour of the right colon (Narrow
 catheter. (d and e) Pulverisation of the polysaccharide powder. (f) Final appearance
2.1.4. Tumours
For  bleeding tumours within the gastrointestinal tract,
endoscopy is an intermediate treatment before more deﬁnitive
treatments, such as surgery or radiotherapy [62], can be conducted.
Endoscopically, bleeding tumours are often very difﬁcult to man-
age because of large, oozing bleeds from fragile vessels caused
by neoangiogenesis. Clips are of limited value because of their
poor anchoring capacity and the fragility of the tumoural tissue.
Epinephrine injections or conventional thermal therapy aggravate
the haemorrhage instead of stopping it. Only APC has the poten-
tial to treat this kind of lesion; the entire area of tumoral tissue
can be treated, although the duration of haemostasis is likely to be
short-lived.
According to the experience of the SEAL group, Hemospray may
also become a treatment for this indication [24]. A recent study
on Hemospray revealed an immediate haemostatic rate of 100%
[26]. Two of the ﬁve patients presented with rebleeding during the
following 7 days.
2.2.  Bleeding lesions related to portal hypertension
2.2.1. Varices
Oesophageal varices are the most frequent aetiology of bleeds
in patients with bleeding lesions related to portal hypertension.
In such cases, the literature is clear about the superiority of band
ligation versus sclerosis for oesophageal varices and type 1 gastro-
oesophageal varices in terms of rebleeding, complications, and
mortality [3,63–66]. For optimal efﬁcacy and minimal adverse
events, ligation must begin at the gastro-oesophageal junction and
move upward in a circular manner.
Historically, until the development of endoscopic and pharma-
cological therapies, bleeding varices were managed using balloon
tamponade (Blakemore and Linton tubes). However, these were
associated with serious adverse events, particularly transmu-
ral oesophageal necrosis. Recently, dedicated expandable stent
placement for oesophageal variceal bleeding has been proven ben-
eﬁcial for this indication, and it uses the same physiopathological
770 J. Jacques et al. / Digestive and Liver Disease 46 (2014) 766–776
Fig. 3. Utilisation of haemostatic forceps for prophylactic and curative coagulation during endoscopic submucosal dissection. (a) Large laterally spreading tumour of the
rectum.  (b) Large vessel that needs prophylactic coagulation (black arrow). (c) Prophylactic coagulation with the haemostatic forceps. (d) Important arterial bleeding during
dissection. (e) Curative coagulation of arterial bleeding using haemostatic forceps. (f) End of dissection.
Fig. 4. Effective haemostasis of a bleeding oesophageal ulcer using band ligation. (a) Bleeding oesophageal ulcer (black arrow). (b) Diluted epinephrine injection. (c) Persistence
of  oozing bleeding despite injection therapy. (d and e) Band ligation with effective cessation of bleeding.
J. Jacques et al. / Digestive and Liver Disease 46 (2014) 766–776 771
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f)  End of the procedure.
neumatic compression. This technique is now recommended as a
escue therapy for patients in whom endoscopic band ligation has
ailed and as a bridge to intravascular transjugular intrahepatic por-
osystemic shunt (TIPS) therapy. The SX Ella Danis (ELLA-CS, s.r.o.,
zech Republic) removable stent is available in Europe, but has not
een approved by the Food and Drug Administration in the United
tates. Few studies have been published on this stent [67–69], but it
as shown a haemostatic efﬁcacy of approximately 90%. The accu-
ulation of more evidence will probably not be possible because
f the small number of cases of refractory variceal bleeds and the
rowing availability of TIPS, which represents the gold standard
herapy for this medical condition [70].
An interventional safety/efﬁcacy study that evaluated Hemo-
pray for the treatment of active variceal bleeding has just been
ublished [71]. Nine patients were involved, and Hemospray
chieved haemostasis in 100% of cases with no rebleeding or
dverse events. Other studies are needed, but these results are
romising in cases of refractory variceal bleeding as a bridge to
IPS therapy.
.2.2. Gastro-oesophageal varices
In patients with type 2 gastro-oesophageal varices and in those
ith isolated gastric varices, injection of cyanoacrylate or tissue
dhesive (Histoacryl or Glubran 2) represents the treatment of
hoice and gives the best results in terms of haemostasis, rebleed-
ng, ulcer scarring, and mortality [72].
For this procedure, a 20-gauge catheter, Lipiodol syringes, and
 Lipiodol–glue mixture syringe are needed. Lubrication of the
orking channel of the scope with the Lipiodol must precede injec-
ion of the Lipiodol–glue mixture into the varix. Suction must be
topped to protect the scope. It is preferable to wait a few seconds
ith the injection needle still within the varix before slowly and
arefully removing the needle. At the end of the procedure, the
cope must be quickly removed and the working channel must beg duodenal angiectasia (black arrows). (c–e) Thermal therapy with the Gold Probe.
carefully brushed. During the procedure, protective eyewear
should be worn to avoid ocular injury to the patient or caregivers.
Endoscopic ultrasonography (EUS) has been used to provide
haemostasis using EUS-guided angiotherapy [73]. High-resolution
EUS images allow for precise visualisation of haemostatic injection
into bleeding vessels. The same coils currently used for radiological
embolisation can also be delivered through a ﬁne-needle aspiration
needle. Several published papers have reported on the haemostatic
efﬁcacy of combined coil–glue therapy, particularly for cases of
refractory gastric variceal bleeding when Doppler monitoring can
be advantageous.
Two  cases in which refractory gastric variceal bleeding was con-
trolled using Hemospray have been reported [20,23] despite the
theoretical contraindication mentioned by the supplier, as it relates
to potential particle- or gas-induced embolism by the device.
2.2.3.  Gastric antral vascular ectasia
Thermal therapies, particularly APC, are the treatment of choice
for gastric antral vascular ectasia (GAVE, or watermelon stom-
ach) [74]. However, multiple sessions are often needed to control
bleeding. Several recent studies have demonstrated the superiority
of endoscopic band ligation, which signiﬁcantly reduces bleeding
events and decreases hospitalisation and transfusion requirements
[75]. In 2008, an American team performed an observational
comparative study involving 22 patients [76]. They showed that
endoscopic band ligation was  superior to APC with a higher rate
of haemostasis, a decrease in the transfusion requirement, and
an increase in haemoglobin levels. Two recent retrospective stud-
ies have conﬁrmed the safety and effectiveness of this procedure
[77,78]. More randomised controlled trials are needed to conﬁrm
these results, but endoscopic band ligation is already considered an
effective alternative therapy for bleeding GAVE.
Preliminary studies have reported on the potential effect
of radiofrequency ablation for GAVE. This procedure, initially
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eveloped for the treatment of dysplasia caused by Barrett’s
esophagus, was ﬁrst used in an American pilot study that enrolled
ix patients. They underwent mucosal ablation with the Halo-
0 device (Covidien, Sunnyvale, CA, USA). The haemoglobin level
mproved from 8.6 to 10.2 g/dL after one to three treatments, and
o adverse events were reported. Five of the six patients were
transfusion-free” during the follow-up period. This pilot study
as just been conﬁrmed in an open-label cohort study of patients
ith GAVE who were refractory to APC [79]. Of the 21 patients
nrolled in this study, 18 were transfusion-independent after one
o three radiofrequency ablation sessions. Their haemoglobin lev-
ls increased from 7.8 to 10.2 g/dL. One minor bleeding episode and
ne superﬁcial ulceration, both treated medically, were considered
dverse events.
Finally,  one recent case series reported on the immediate and
rolonged effectiveness of Hemospray in three patients with bleed-
ng portal hypertension gastropathy [30].
. Lower gastrointestinal bleeding
An emergency colonoscopy is the key procedure for severe
aematochezia, both for its diagnosis and for potential endoscopic
aemostasis [80]. The diagnostic and therapeutic yield is often low,
nd optimised oral preparation and the use of a washing pump are
referred as often as possible. Diverticular bleeding, angiectasia,
schaemic colitis, internal haemorrhoids, and radiation proctitis are
he most common causes of lower gastrointestinal bleeding.
.1.  Diverticular bleeding
In  diverticular bleeding, identiﬁcation of an active bleeding site
r suggestive stigmata, such as an adherent clot or a visible ves-
el, is difﬁcult. In cases in which the source of bleeding has been
ell evaluated, all of the conventional tools (injection therapy,
hermal therapy, and clips) can be used; however, clips seem to
e safer and can serve to locate the area of bleeding for eventual
mbolisation [81]. Several researchers have described successful
ndoscopic therapy with band ligation and have achieved inversion
f the diverticulum using suction [82].
.2. Angiectasia
Coagulation with APC is the procedure most often proposed as
he ﬁrst-line treatment for angiectasia [83]. Oral preparation with
olyethylene glycol is necessary because of the risk of colonic per-
oration, as has been described with enema preparations [84–87].
ther thermal therapies are also effective (Fig. 5), but have a higher
isk of perforation [83].
.3.  Radiation proctitis
Radiation  proctitis occurs in 5–20% of patients treated by pelvic
adiotherapy [88]. Spontaneous resolution occurs in most patients,
ut some develop chronic radiation proctitis with recurring bleed-
ng episodes that lead to multiple hospitalisations and blood
ransfusions. Endoscopic therapy can be effective for this condition.
Thermal therapies are typically used for this indication, particu-
arly APC [89–92] because of its ease of use, safety, availability, and
ost. Settings differ slightly among published studies, with the ﬂow
ate oscillating from 0.8 to 2.0 mL/min and the power ranging from
0 to 65 W [93]. All other thermal therapies (monopolar and bipo-
ar probes, YAG laser) have been supplanted by the development of
PC.
Promising results have been published on the use of radiofre-
uency ablation using the HALO90 radiofrequency system
Covidien, Sunnyvale, CA, USA) on ﬁve patients [94]. More patients Disease 46 (2014) 766–776
have  probably been treated with this device because several small
series have been presented at various gastroenterological con-
gresses.
Anecdotal reports exist on the potential efﬁciency of a cryoabla-
tion system [95] (CryoSpray; CSA Medical, Lutherville, MD,  USA) to
treat proctitis caused by radiation, and larger studies are expected.
4. Bleeding during interventional endoscopic procedures
The  number of interventional endoscopic procedures has
increased greatly over the last two decades and has allowed for
endoscopic therapy for ever-larger lesions. Of particular impor-
tance is the development of ESD. Bleeding, initially considered
to be a complication at the time of polypectomy 20 years ago, is
now an integral part of the procedure. Prevention and treatment of
bleeding is a prerequisite before starting interventional endoscopic
procedures.
4.1. Polypectomy
Different risk factors have been identiﬁed for polypectomy, but
the major risk factor for bleeding after polypectomy is the size of
the polyp [96,97]. Table S1 shows the overall risk factors for post-
polypectomy bleeds [96–100].
Recommendations  by the European Society of Gastrointestinal
Endoscopy (ESGE) [101] and the American Society of Gastroin-
testinal Endoscopy (ASGE) [102] have permitted polypectomy in
patients treated with aspirin, but not other antiplatelet agents or
anticoagulants.
If one or more risk factors for bleeding is present, particu-
larly a polyp size of >20 mm,  an epinephrine injection and/or loop
placement may  prevent postpolypectomy bleeding; a recent meta-
analysis conﬁrmed a decrease in post-polypectomy bleeding using
these techniques [103]. When loop placement fails or is not feasible
in the absence of a postpolypectomy stump, clips are a reasonable
alternative solution [104]. Clips should be applied when a vessel is
visible after polypectomy.
If  immediate bleeding is observed, grasping the stalk with the
polypectomy snare and holding it for 5–10 min  is the quickest
method to stop bleeding. This permits the endoscopy staff to
prepare clips, an injection needle, or haemostatic forceps before
haemorrhage obscures the ﬁeld.
In cases of delayed bleeding, all haemostatic endoscopic proce-
dures can be used with the exception of thermal therapy in the right
colon because of the increased risk of perforation in this location. If
that is the only option available, the use of thermal therapy in the
right colon necessitates extreme caution.
4.2. Endoscopic submucosal dissection (ESD)
ESD is associated with the greatest risk of bleeding; the risk fac-
tors for bleeding [105] are listed in Table S2. All anti-platelet agents,
including aspirin, must be stopped [101].
During the procedure (intraprocedural bleeding), prophylactic
coagulation with dissection knives or haemostatic forceps is neces-
sary [106]. Oozing bleeding can usually be managed with a knife; in
contrast, arterial bleeding requires haemostatic forceps [107,108]
(Fig. 3). Clips are reserved for uncontrolled bleeding or at the end
of a dissection because they can interfere with the ESD procedure
[109]. An epinephrine injection and compression by the tip of the
endoscope can also be useful.
With respect to post-procedural bleeding, infusion of proton-
pump inhibitors plays a key role in preventing bleeds after
gastric ESD [110]. Prophylactic coagulation of all visible vessels is
recommended [108]. Several authors have recommend a system-
atic second-look endoscopy to prevent post-procedural bleeding
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rig. 6. Bleeding post-duodenal endoscopic mucosal resection managed by haemocl
 polypectomy snare. (c) End of resection with a scar. (d) Oozing bleeding 3 min  aft
ethod. (g and h) Efﬁcacy of the procedure at the end of closure.
111,112] in cases of gastric ESD; however, these results must be
onﬁrmed in a larger trial. Finally, one recent Chinese study of
71 patients reported signiﬁcant efﬁcacy of cyanoacrylate used as
 spray [113] and applied at the end of the procedure to reduce
ost-procedural bleeding (0.00% vs. 4.88%; p = 0.035).
.3. Endoscopic mucosal resection (EMR)
The bleeding risk associated with EMR  lies between that of
olypectomy and ESD. Intraprocedural and clinically signiﬁcant
elayed bleeding must be differentiated. A recent large prospective
bservational study of 1172 patients [114] treated by wide-ﬁeld
MR of large sessile colonic lesions reported a 11.3% intraprocedu-
al bleeding rate and a 6.2% clinically signiﬁcant post-EMR bleeding
ate. According to the multivariate analysis, a larger lesion, Paris
lassiﬁcation of 0–IIa + Is, and tubulovillous or villous histology
ere associated with a higher risk of immediate bleeding. Loca-
ion in the proximal colon and duodenum, use of an electrosurgical
urrent not controlled by a microprocessor, and the presence of an
mmediate bleed were associated with an increased risk of delayed
leeding.The ESGE [101] and ASGE [102] recommend that all anti-platelet
gents are stopped, including aspirin. However, the results of a large
ulticentre French registry called OPERA (NCT01481337) were
ecently presented at a French gastroenterological congress and) Large duodenal adenoma after submucosal injection. (b) Monobloc resection with
 end of resection. (e and f) Management of bleeding by scar closure using the “zip”
indicated  with a low immediate and delayed bleeding risk (6.18%
and 1.00%, respectively) in patients taking aspirin. Another French
multicentre study called MEDOC (NCT01807169) has just started
evaluating the incidence of immediate and delayed bleeding after
polypectomy or EMR  among patients receiving clopidogrel.
Prophylactic haemostasis of all visible vessels with haemostatic
forceps can prevent delayed bleeding. The closing of scars (Fig. 6)
with clips prevented delayed bleeding in two retrospective studies
[109,115], but prospective data are lacking to conﬁrm these results
[116,117]. If an intra-procedural bleed occurs during piecemeal
resection, an epinephrine injection and haemostatic forceps are
preferred because clips can interfere with the resection procedure.
The choice of the electrosurgical unit and its settings is also
very important. A pure cutting current is associated with a higher
rate of intra-procedural bleeding [118,119], and a pure coagulating
current is associated with a higher rate of delayed bleeding [120].
4.4.  Sphincterotomy
There are many risk factors that can increase the chance of
bleeding during sphincterotomy (Table S3); among them, aspirin
is the only anti-platelet agent authorised by both the ESGE [101]
and ASGE [102].
An  injection of epinephrine is the method of choice because
it is easy, economical, and highly effective [121]. The injection is
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ade at the apex of the sphincterotomy or 20–30 mm above the
ite because of the vascular anatomy of the papilla [122,123].
Clips  and thermal therapies have the same disadvantages [121]:
hey are difﬁcult to manipulate with a side-viewing endoscope, it
s difﬁcult for the elevator to raise them into view because of their
tiffness, and there is a signiﬁcant risk of pancreatitis.
In cases of uncontrolled bleeding, despite classical haemostatic
rocedures, several publications have reported excellent results
>90% haemostasis rate) with a fully covered stent when used as
 salvage therapy [124,125].
Hemospray  has also been successfully used for this indication
n several cases, but one report describes the risk of obstructing the
ost-sphincterotomy biliary oriﬁce [29].
.5. Therapeutic endoscopic ultrasound (EUS)
Bleeding is a potentially life-threatening complication after EUS
rainage of pancreatic ﬂuid. Endoscopic management is very difﬁ-
ult and is limited to balloon tamponade, thermal therapy, and an
drenaline injection. Embolisation or surgery is required in cases
f refractory bleeding. Preliminary data suggest the efﬁciency of a
ully covered biliary metal stent (as used in post-sphincterotomy
leeding) or an EUS-guided cyano-acrylate injection [126,127].
arger studies are needed to further assess these procedures.
.  Conclusion
In the last decade, the toolbox of endoscopic haemostasis
as grown in parallel with the number of devices available for
ndotherapy (Figs. 1 and 2). Haemostatic powders, OTSCs, haemo-
tatic forceps, and other emerging technologies have changed daily
ractise and offer diverse possibilities to stop bleeding. Endoscopic
aemostasis is obviously an inherent part of the management
f bleeding; it includes ﬂuid and blood resuscitation and medi-
al therapy, particularly proton-pump inhibitors and vasoactive
rugs (e.g., somatostatin, octreotide, terlipressin). Although evi-
ence from studies on new procedures is not strong, it is very
ifﬁcult to design a high-power trial of gastrointestinal bleeding;
hus, the use of large registries is probably a good alternative.
Familiarity of these emerging technologies, particularly via ex
ivo and in vivo pig models, is needed before they are extensively
sed on humans. Moreover, it should not be forgotten that over-
oming endoscopic haemostasis is the ﬁrst step before starting
ndoscopic interventional procedures.
The best combination for endoscopic haemostasis should obtain
he highest rate of haemostasis while minimising the rates of
ebleeding and adverse events, be easy to use in all locations, and
e inexpensive [27]. This is the goal of endoscopic haemostasis and
ill decrease the indications that may  require radiological emboli-
ation and/or surgery [128]. Trials and registries are needed to
chieve this goal.
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